Development and Validation of a Decision-Making Stratification Algorithm to Optimize the Use of Rapid Diagnostic Testing for Patients with Staphylococcus Bacteremia
Table 1
Patients who met inclusion criteria for rapid diagnostic testing.
Age
Gender
Empiric therapy
Isolated microorganism
Plan made
Time to optimal antibiotic therapy (hours) using culture based method
Expected time avoided (hours) to optimal antibiotic therapy using the molecular diagnostic test
61
F
Vancomycin
MSSA
Changed to nafcillin
78
74
68
M
Vancomycin
CoNS
Vancomycin discontinued
44
42
32
F
Vancomycin and levofloxacin
CoNS
Discharged from ED
n/a
78
F
Vancomycin
CoNS
Vancomycin discontinued
30
28
74
F
Vancomycin and doxycycline
CoNS
Vancomycin discontinued and patient discharged
49
47
49
M
Vancomycin
CoNS
Discharged from ED
n/a
80
F
Vancomycin and ceftriaxone
Micrococcus
Vancomycin discontinued
28
26
85
F
Vancomycin and piperacillin/tazobactam
CoNS
Vancomycin discontinued
22
20
29
M
Vancomycin
CoNS
Vancomycin discontinued
31
29
F = female, M = male, MSSA = methicillin-susceptible Staphylococcus aureus, CoNS = coagulase-negative staphylococci, and ED = emergency department. Patients were called to return for emergency department evaluation, to assess clinical status and repeat blood cultures.